Background
==========

In Canada and the United States (U.S.), levels of Prescription Opioid Analgesic (POA) use have been rising since 2000; globally, Canada and the U.S. have the highest levels of POA use \[[@B1]\]. In this context, POA-related morbidity and mortality levels have also increased in recent years \[[@B2]-[@B6]\], constituting a major public health problem.

A key epidemiological indicator of POA-related problems is the prevalence of Non-Medical Prescription Opioid Use (NMPOU), which is defined as using POAs when they are not prescribed by a physician, or using POAs for purposes other than as prescribed; the definition of NMPOU excludes the underuse of POAs. The prevalence of NMPOU is strongly correlated to levels of POA-related morbidity and mortality \[[@B6]\], and hence the prevalence of NMPOU in the general population needs to be accurately identified for targeted preventive interventions \[[@B6]-[@B9]\].

NMPOU, can be defined and operationalized in different ways. For example, the Canadian Alcohol and Other Drug Use Monitoring Survey (CADUMS) initially surveyed NMPOU in the Canadian general adult population (15+ years) in 2008 based on the following questions: 1) "During the past 12 months, did you ever use pain relievers for the feelings \[they\] caused or to get high?", and/or 2) Were the pain relievers used during the past 12 months obtained from i) "a prescription written for someone else such as a family member or a friend," ii) "bought from someone else, without a prescription," iii) "from any other source" \[[@B10]\]. On this basis, the CADUMS found an NMPOU prevalence of 0.4%, which amounted to about one-tenth of the NMPOU prevalence of 4.8% estimated for the United States (U.S.) general youth and adult (12+ years) population in 2008 by the National Survey on Drug Use and Health (NSDUH) \[[@B11],[@B12]\].

In contrast to the CADUMS, NMPOU is defined in the NSDUH as having provided the answer "yes" to the question: "Have you ever, even once, used (name of prescription opioid) that was not prescribed for you or that you took only for the experience or feeling it caused?" \[[@B12]\]. Given the amount of POAs that are prescribed in Canada and in the U.S., and the association between \`POA use and NMPOU \[[@B13]\], NMPOU prevalence estimates for Canada should be approximately half the prevalence of NMPOU in the U.S. Differences in the prevalence estimates of NMPOU obtained from the CADUMS and from the NSDUH may be due in part to variations in the formulation of questions asked in each of these surveys which result in differing responses. As measurement differences in NMPOU have not been investigated, there is a timely need and opportunity to investigate estimate variations that may arise from differences in how NMPOU is operationalized.

Methods
=======

To examine potential measurement effects for assessing the prevalence of NMPOU in Canada, we tested an alternative NMPOU item constructs in the Centre for Addiction and Mental Health (CAMH) Monitor surveys \[[@B14],[@B15]\].The 2008, 2009 and 2010 CAMH Monitor surveys employed a two-stage, probability sample based, computer-assisted telephone interviewing, random-digit dialing method, and sampled the Ontario general adult population (18+ years). Each month of the survey a sampling frame of all active area codes and exchanges in Ontario was obtained from ATI long lines tape. Telephone numbers from this source, as well as telephone numbers between or on either side of listed numbers were included in the sampling frame. This method allowed for any person with a home phone (listed or unlisted) or a cellphone to be included in the sampling frame; however, a proportion of people with an unlisted number and/or a cellphone were not included in the sampling frame. The sampling frame was then stratified into regions (based on counties) as follows: Toronto, Central West Ontario, Central East Ontario, West Ontario, East Ontario, and North Ontario (see \[[@B14]-[@B16]\] for the exact counties included within each region). Within each stratum, a random sample of telephone numbers was selected with equal probability. To increase the response rate in the stratum of Toronto, a letter was sent to the selected household informing them that they would be contacted and describing the history and objectives of the CAMH Monitor survey. Within selected households, the respondent who was 18 years of age or older, who had the most recent birthday of the eligible household members, and who could complete the interview in either English or French was selected to participate in the survey. A minimum of 12 call-backs were placed to unanswered numbers and all households who refused to participate on the first contact were re-contacted and asked again to participate. No incentive was offered for participation. The procedures and interviews of each cycle of the CAMH Monitor surveys were approved by the CAMH Research Ethics Board \[[@B14],[@B15]\].

NMPOU questions in the 2008 and 2009 waves of the CAMH Monitor surveys were asked from July to December, whereas the 2010 NMPOU data were collected from January to December of the respective year. Response rates for the CAMH Monitor surveys were calculated using the method proposed by the American Association for Public Opinion Research (response rate calculation \#3) which takes into account in the response rate calculation the number of telephone numbers which may be eligible to be included in the survey \[[@B14]-[@B16]\]. This formula for calculating the response rate is as follows:

$$\mathit{RR} = \frac{I}{\left( {I + P} \right) + \left( {R + \mathit{NC}} \right) + e\left( \mathit{UH} \right)}$$

where I represents the number of completions, P represents the number of partial completions, R represents the refusals/breakoffs, NC represents non-contacts, e represents the estimated proportion of cases of unknown eligibility that are eligible, and UH represents the number of telephone numbers which may be eligible to be included in the survey.

In the 2008, 2009 and 2010 waves of the CAMH Monitor surveys POAs were defined as "pain relievers that are obtained by a prescription from a doctor or dentist such as Percocet, Percodan, Demerol, OxyContin, Tylenol \#3 or other products or pain relievers with codeine that are obtained in a pharmacy. Some people use these medications to treat pain resulting from an illness, injury." NMPOU in the 2008 and 2009 waves of the CAMH Monitor surveys was measured similarly to the CADUMS questions described above as follows: 1) "Thinking about all the pain relievers you have used during the past 12 months did you get any of them" i) "from a prescription written for someone else such as a family member or a friend", ii) "bought from someone else, without a prescription" and/or iii) "from any other source (defined as a source other than the previously mentioned sources and a prescription written for you)," and 2) "During the past 12 months, did you ever use pain relievers for the feelings it caused or to get high?" The alternative NMPOU item tested in the 2010 wave of the CAMH Monitor survey was based on the question: "In the past 12 months how many times, if at all, have you used any such pain relievers without a prescription or without a doctor telling you to take them?"

The items used in the 2008 and 2009 waves of the CAMH Monitor surveys were initially pretested with 25 respondents in November 2007 and included as a pilot study in December of the 2007 wave of the CAMH Monitor survey (N = 175). Applicable questions were asked at the end of the POA items in the 2009 cycle of the CAMH Monitor survey to evaluate the response process; 96.4% of respondents declared that the questions on POA use were not difficult to understand, and 96.1% of respondents did not need the questions to be repeated to them before answering \[[@B17]\]. The items used in the 2010 wave of the CAMH Monitor survey were also initially asked in the 2007 and the 2009 cycles of the Ontario Student Drug Use and Health Survey. These questions were revised for the 2010 wave of the CAMH Monitor survey based on pretesting which confirmed item comprehension and feasibility.

For our analysis of the difference in the measurement effect of the alternative NMPOU survey items on the estimated prevalence of NMPOU, we controlled for the following demographic variables: age (grouped into three categories: 18--29, 30--54, 55+), region (living in Toronto, the rest of Ontario), and household income (\<\$30,000, \$30,000--79,000, \$80,000+, not stated). The substance use variables we controlled for in our analysis were tobacco use (defined as either daily or occasional (during the last 12 months) cigarette smoking), weekly binge drinking (defined as drinking five or more drinks on one occasion at least once a week in the previous 12 months), and cannabis use (defined as using cannabis at least once in the previous 12 months).

We also controlled for psychological distress, as measured by the 12-item General Health Questionnaire (GHQ-12). The GHQ-12 is a screening instrument that evaluates depression/anxiety and problems with social functioning \[[@B18]\] and we used a cut-off score of 3 or more on the GHQ-12 as an indication of elevated psychological distress.

All statistical analyses were performed using population expansion weights. Population expansion weights were constructed using census data from Statistics Canada on the number of people living in each stratum by age (using the age categories of 18-24, 25-44, 45-64, 65+) and by sex \[[@B14]-[@B16]\]. Significant differences between prevalence estimates were calculated using chi-square tests with a second-order Rao-Scott adjustment for survey data for the unadjusted analysis \[[@B19]\]. For the unadjusted and adjusted regression analyses, we employed a general linear model adjusted for survey design. All statistics were performed using the statistical software package R version 2.15.1 \[[@B20]\], and the statistical software package Survey (a statistical package for R) \[[@B21]\].

Results
=======

The CAMH Monitor survey response rates were 56.6% for July to December in 2008, 57.5% for July to December in 2009, and 50.6% for January to December in 2010. The NMPOU items run in the 2008 and 2009 waves of the CAMH Monitor surveys had valid data for n = 1,021 (effective response rate of 56.1%) for 2008 and n = 996 (effective response rate of 57.1%) for 2009 respectively. The NMPOU item run in the 2010 wave of the CAMH Monitor survey had valid data for n = 2,015 (effective response rate of 50.2%). The response rates for the 2008, 2009 and 2010 waves of the CAMH Monitor surveys did not vary significantly by month.

Table [1](#T1){ref-type="table"} outlines the prevalence estimates for the different NMPOU items run in the 2008 and 2009 CAMH Monitor survey samples and in the 2010 CAMH Monitor survey sample. Table [2](#T2){ref-type="table"} outlines the prevalence of NMPOU by gender. The prevalence of NMPOU in Ontario in 2008 and 2009 as measured by the 2008 and 2009 waves of the CAMH Monitor surveys was 2.0% (95% Confidence Interval (CI): 1.2% to 2.8%) (2.3% for 2008 and 1.7% for 2009), and was 7.7% (95% CI: 6.3% to 9.2%) in 2010 as measured by the 2010 wave of the CAMH Monitor survey. This difference in the measured prevalence of NMPOU in the 2008 and 2009 CAMH Monitor surveys and in the 2010 CAMH Monitor survey was significant (p \<0.001). Significant differences between the NMPOU items were also observed when the analysis was stratified by sex (p \<0.001 for women and p \<0.001 for men). The Additional file [1](#S1){ref-type="supplementary-material"}: Web appendix outlines these prevalence estimates using no weights.

###### 

Characteristics of Ontario adults (18+ years) as measured by the 2008, 2009 and 2010 CAMH Monitor surveys

                                         **CAMH Monitor 2008 and 2009**   **CAMH Monitor 2010**                                    
  ------------------------------------- -------------------------------- ----------------------- ------------------ ------ ------- ------------------
  Gender                                                                                                                           
  Men                                                 896                         50.5%           (47.8% to 53.2%)   887    49.8%   (47.1% to 52.5%)
  Women                                               1134                        49.5%           (46.8% to 52.2%)   1137   50.2%   (47.5% to 52.9%)
  Age (years)                                                                                                                      
  18--29                                              295                         26.7%           (23.8% to 29.5%)   319    28.2%   (25.4% to 31.1%)
  30--54                                              826                         43.1%           (40.4% to 45.8%)   756    39.6%   (36.0% to 42.3%)
  55+                                                 844                         30.2%           (28.0% to 32.5%)   912    32.1%   (29.8% to 34.4%)
  Region                                                                                                                           
  Toronto                                             317                         21.1%           (19.2% to 23.0%)   332    21.9%   (19.9% to 23.8%)
  Rest of Ontario                                     1713                        78.9%           (77.0% to 80.8%)   1692   78.1%   (76.2% to 80.1%)
  Income                                                                                                                           
  \<\$30,000                                          250                         8.5%             (7.1% to 9.9%)    242    8.7%    (7.2% to 10.1%)
  \$30,000 to \$49,999                                254                         10.4%           (8.9% to 11.9%)    269    10.4%   (9.0% to 11.9%)
  \$50,000 to \$79,999                                390                         19.2%           (17.2% to 21.3%)   370    17.7%   (15.7% to 19.7%)
  \$80,000+                                           619                         35.0%           (32.4% to 37.6%)   670    38.7%   (36.1% to 41.4%)
  Not stated                                          517                         26.9%           (24.4% to 29.3%)   473    24.5%   (22.1% to 26.8%)
  Prescription opioid use                                                                                                          
  Yes                                                 475                         21.3%           (19.1% to 23.4%)   485    23.1%   (20.8% to 25.3%)
  No                                                  1543                        78.7%           (76.6% to 80.9%)   1515   76.9%   (74.7% to 79.2%)
  Non-medical prescription opioid use                                                                                              
  Yes                                                  40                         2.0%             (1.2% to 2.8%)    143    7.7%     (6.3% to 9.2%)
  No                                                  1977                        98.0%           (97.2% to 98.8%)   1872   92.3%   (90.8% to 93.7%)
  Cigarette smoking                                                                                                                
  Current                                             399                         18.9%           (16.8% to 21.0%)   373    19.4%   (17.2% to 21.6%)
  Former                                              654                         28.2%           (25.9% to 30.4%)   654    28.2%   (25.9% to 30.6%)
  Never smoker                                        973                         52.9%           (50.2% to 55.6%)   991    52.4%   (49.7% to 55.1%)
  Weekly binge drinking                                                                                                            
  Yes                                                 133                         7.9%             (6.4% to 9.4%)    144    8.2%     (6.7% to 9.8%)
  No                                                  1883                        92.1%           (90.6% to 93.6%)   1866   91.8%   (90.2% to 93.3%)
  Cannabis use (past 3 months)                                                                                                     
  Yes                                                 148                         10.1%           (8.3% to 12.0%)    186    12.0%   (10.0% to 14.0%)
  No                                                  1876                        89.9%           (88.0% to 91.7%)   1838   88.0%   (86.0% to 90.0%)
  Psychological distress (GHQ 3+)                                                                                                  
  Yes                                                 284                         13.4%           (11.5% to 15.2%)   277    14.6%   (12.6% to 16.6%)
  No                                                  1743                        86.6%           (84.8% to 88.5%)   1746   85.4%   (83.4% to 87.4%)

###### 

Characteristics of Ontario adults (18+ years) as measured by the 2008, 2009 and 2010 CAMH Monitor surveys by gender

                                         **Women**   **Men**                                                                                                      
  ------------------------------------- ----------- --------- ------------------ ------ ------- ------------------ ----- ------- ------------------ ----- ------- ------------------
  Age (years)                                                                                                                                                     
  18--29                                    147       26.2%    (22.1% to 30.2%)   157    24.5%   (21.0% to 28.0%)   148   27.1%   (23.2% to 31.1%)   162   32.0%   (27.7% to 36.3%)
  30--54                                    454       42.9%    (39.2% to 46.6%)   414    40.5%   (37.0% to 44.0%)   372   43.3%   (39.4% to 47.2%)   342   38.8%   (34.9% to 42.6%)
  55+                                       488       30.9%    (27.9% to 34.0%)   545    35.0%   (31.8% to 38.1%)   356   43.3%   (40.0% to 46.6%)   367   38.8%   (35.5% to 42.0%)
  Region                                                                                                                                                          
  Toronto                                   179       21.7%    (18.7% to 24.8%)   196    23.6%   (20.7% to 26.5%)   138   20.5%   (17.4% to 23.6%)   136   20.1%   (16.9% to 23.4%)
  Rest of Ontario                           955       78.3%    (75.2% to 81.3%)   941    76.4%   (73.5% to 79.3%)   758   79.5%   (76.4% to 82.6%)   751   79.9%   (76.6% to 83.1%)
  Income                                                                                                                                                          
  \<\$30,000                                163       9.8%     (7.9% to 11.7%)    156    9.5%    (7.7% to 11.4%)    87    7.2%     (5.3% to 9.2%)    86    7.8%    (5.6% to 10.0%)
  \$30,000 to \$49,999                      139       10.1%    (8.1% to 12.1%)    164    11.4%   (9.3% to 13.4%)    115   10.7%   (8.4% to 12.9%)    105   9.5%    (7.4% to 11.6%)
  \$50,000 to \$79,999                      216       19.5%    (16.7% to 22.3%)   189    16.7%   (14.1% to 19.3%)   174   19.0%   (16.0% to 12.9%)   181   18.7%   (15.7% to 21.8%)
  \$80,000+                                 290       30.7%    (27.2% to 34.3%)   336    35.3%   (31.8% to 38.7%)   329   19.0%   (15.2% to 22.7%)   334   18.7%   (14.7% to 22.7%)
  Not stated                                326       29.9%    (26.4% to 33.3%)   292    27.1%   (23.9% to 30.4%)   191   23.9%   (20.4% to 27.4%)   181   21.8%   (18.3% to 25.2%)
  Prescription opioid use                                                                                                                                         
  Yes                                       279       22.7%    (19.6% to 25.7%)   293    24.7%   (21.7% to 27.7%)   196   19.9%   (16.9% to 22.9%)   192   21.4%   (18.1% to 24.8%)
  No                                        848       77.3%    (74.3% to 80.4%)   829    75.3%   (72.3% to 78.3%)   695   80.1%   (77.1% to 83.1%)   686   78.6%   (75.2% to 81.9%)
  Non-medical prescription opioid use                                                                                                                             
  Yes                                       20        1.6%      (0.8% to 2.5%)     77    7.4%     (5.5% to 9.3%)    20    2.4%     (1.0% to 3.7%)    66    8.1%    (5.9% to 10.3%)
  No                                       1106       98.4%    (97.5% to 99.2%)   1058   92.6%   (90.7% to 94.5%)   871   97.6%   (96.3% to 99.0%)   814   91.9%   (89.7% to 94.1%)
  Cigarette smoking                                                                                                                                               
  Current                                   194       15.2%    (12.6% to 17.7%)   188    15.7%   (13.1% to 18.2%)   205   22.6%   (19.3% to 25.9%)   185   23.1%   (19.6% to 26.7%)
  Former                                    342       25.9%    (22.9% to 28.9%)   340    26.1%   (23.1% to 29.0%)   312   30.4%   (27.0% to 33.8%)   314   30.4%   (26.9% to 34.0%)
  Never smoker                              595       59.0%    (55.4% to 62.5%)   607    58.3%   (54.8% to 61.7%)   378   47.0%   (43.0% to 50.9%)   384   46.4%   (42.4% to 50.5%)
  Weekly binge drinking                                                                                                                                           
  Yes                                       27        2.9%      (1.5% to 4.4%)     29    3.3%     (1.9% to 4.6%)    106   12.8%   (10.2% to 15.5%)   115   13.2%   (10.4% to 16.0%)
  No                                       1102       97.1%    (95.6% to 98.5%)   1102   96.7%   (95.4% to 98.1%)   781   87.2%   (84.5% to 89.8%)   764   86.8%   (84.0% to 89.6%)
  Cannabis use (past 3 months)                                                                                                                                    
  Yes                                       46        6.1%      (4.0% to 8.2%)     61    6.3%     (4.5% to 8.2%)    102   14.1%   (11.1% to 17.0%)   125   17.7%   (14.2% to 21.1%)
  No                                       1084       93.9%    (91.8% to 96.0%)   1076   93.7%   (91.8% to 95.5%)   792   85.9%   (83.0% to 88.9%)   762   82.3%   (78.9% to 85.8%)
  Psychological distress (GHQ 3+)                                                                                                                                 
  Yes                                       178       16.3%    (13.5% to 19.1%)   180    16.8%   (14.0% to 19.5%)   106   10.5%   (8.2% to 12.9%)    97    12.4%   (9.5% to 15.3%)
  No                                        954       83.7%    (80.9% to 86.5%)   957    83.2%   (80.5% to 86.0%)   789   89.5%   (87.1% to 91.8%)   789   87.6%   (84.7% to 90.5%)

Table [3](#T3){ref-type="table"} outlines the unadjusted and adjusted odds ratios for NMPOU by survey and gender. When comparing the 2008 and 2009 waves to the 2010 wave of the CAMH Monitor surveys, the odds of NMPOU increased by 3.99 (95% CI: 2.52 to 6.31) when not adjusting for any covariates, and by 4.12 (95% CI: 2.66 to 6.37) when adjusting for all confounding covariates. The interaction between gender and survey year on the odds of NMPOU was not found to be significant (p \> 0.10).

###### 

Odds ratios of non-medical prescription opioid use as measured by the 2010 CAMH Monitor survey compared to the 2008 and 2009 CAMH Monitor surveys

                                                                                **Total**      **Men**       **Women**                          
  ------------------------------------- ---------------------- --------------- ----------- ---------------- ----------- ---------------- ------ ----------------
  Non-medical prescription opioid use    Model 1 (Unadjusted)       2010          3.99      (2.52 to 6.31)     3.60      (1.89 to 6.88)   4.58   (2.46 to 8.54)
                                                                2008 and 2009      REF            \-            REF            \-         REF          \-
                                          Model 2 (Adjusted)        2010          4.12      (2.66 to 6.37)     3.96      (2.27 to 6.93)   4.90   (2.69 to 8.95)
                                                                2008 and 2009      REF            \-            REF            \-         REF          \-

Model 2 was adjusted for the following variables: gender (only for the regression including both men and women), age, region, income, prescription opioid use, cigarette smoking, weekly binge drinking, cannabis use (past three months) and psychological distress.

Discussion
==========

Our results suggest that NMPOU survey estimates differ markedly depending on the question items used. The estimated prevalence of NMPOU in Ontario is approximately 210,000 people (derived from population estimates of Ontario in 2010) when based on the estimates from the 2008 and 2009 CAMH Monitor surveys, and 808,700 people (derived from population estimates of Ontario in 2010) when based on the 2010 CAMH Monitor survey\[[@B22]\].

Self-reported non-medical drug use is a subjective concept, and difficult to measure as it is commonly under-reported in surveys, with cognitive models of survey interviews suggesting that reporting errors originate from i) poor comprehension of the questions asked, ii) inaccurate recall of the information, and iii) deliberate misreporting of information \[[@B23]\]. The NMPOU questions in the 2008 and 2009 CAMH Monitor surveys asked about the source and the use of POA, while the NMPOU question in the 2010 CAMH Monitor survey asked the participant whether they used prescription opioids without a prescription or a doctor telling them to do so. Additionally, some of the NMPOU items may deal with the illicit use of drugs, a socially disapproved of and unlawful behaviour, which may have led participants in the 2008 and 2009 CAMH Monitor surveys to edit their responses \[[@B23]-[@B25]\].

Limitations
-----------

It is important to note that NMPOU may have actually increased and/or the determinants of NMPOU may have changed between 2008, 2009, and 2010, although it is highly unlikely that the entirety of the observed differences in NMPOU prevalence can be explained by these factors \[[@B26]\]. When comparing the difference in the NMPOU prevalence in the CAMH Monitor surveys to the U.S. data for trends in the prevalence of NMPOU in the same three years (4.8% for 2008, 4.9% for 2009 and 4.8% for 2010 \[[@B11],[@B12],[@B27]\]), it seems unrealistic to suggest that the difference found in our study between 2008/2009 and 2010 is completely attributable to such a major increase in NMPOU. Additionally, to control for a potential change in the determinants of NMPOU, we performed a regression analysis that controlled for the covariates of gender (only for the regression that included both men and women), age, region, income, prescription opioid use, cigarette smoking, weekly binge drinking, cannabis use in the past three months, and psychological distress, which have been shown to be associated with NMPOU \[[@B28]\]. Thus, the observed difference in the prevalence estimates for 2008/2009 versus 2010 is likely due to measurement error.

Both prevalence estimates of NMPOU are also biased by factors other than the question used to measure NMPOU, and thus are likely underestimates of NMPOU in Ontario. The CAMH Monitor was a telephone-based population survey and excluded people who did not own a phone. This excluded group includes homeless individuals who have been shown to be more likely to use prescription opioids than the general popula-tion \[[@B29]\], thereby leading to a probable underestimation of the prevalence of NMPOU. In addition to excluding people who do not have a phone, the surveys also excluded people who did not speak either English or French; however, there were very few people excluded from the 2008, 2009, or 2010 CAMH Monitor surveys because they did not speak either English or French \[[@B14]-[@B16]\]. An additional difficulty with telephone surveys is that those people who are unlikely to respond are more likely to engage in habits that are detrimental to their health \[[@B30]\]. To obtain accurate estimates of NMPOU in Ontario, both the question item constructs and protocols used to calculate these prevalence estimates need to be improved.

Conclusions
===========

The results of this study demonstrate that we cannot be certain to have a reliable or valid general population survey estimates of the number of individuals engaging in NMPOU in Canada. Thus, validity studies investigating the effects of NMPOU items on a study participant's comprehension, interpretation, information retrieval, judgment formation, and response editing, are needed to validate current measures and to create improved, standardized measures of NMPOU in order to generate more reliable or valid estimates of the number of individuals engaging in NMPOU in Canada.

In summary, given the morbidity and mortality impact of NMPOU and the requirement for evidence-based targeted interventions, there is an urgent need to systematically develop, validate, and standardize NMPOU items for future general population surveys \[[@B31]\].
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